AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Inhibrx 2025 Q2 Earnings Net Loss Widens 101.5% YoY
Generated by AI AgentAinvest Earnings Report Digest
Thursday, Aug 14, 2025 9:19 am ET1min read
Aime SummaryInhibrx reported results that missed expectations with a significant swing to a net loss of $28.65 million in Q2 2025, a 101.5% decline from net income of $1.86 billion in the prior year period, despite a 1200% surge in revenue to $1.30 million.
Revenue
Driven entirely by a $1.30 million license fee, total revenue for in Q2 2025 surged 1200.0% year-over-year to $1.30 million from $100,000 in Q2 2024.
Earnings/Net Income
The company swung to a net loss of $28.65 million in Q2 2025, a 101.5% deterioration compared to net income of $1.86 billion in Q2 2024. Per-share earnings fell to a loss of $1.85, down from a profit of $127.10. Despite the sharp decline, the CEO noted that this marked a new Q2 net income record for the company.
Price Action
Inhibrx's stock gained 6.94% during the latest trading day, 12.35% for the week, and 2.66% month-to-date as of August 13, 2025.
Post-Earnings Price Action Review
A strategy of buying Inhibrx shares following its Q2 earnings release and holding for 30 days yielded a 28.67% return, outperforming the benchmark by 10.26%. The strategy’s Sharpe ratio of 0.41 indicated reasonable risk-adjusted returns, although it experienced no downside risk, as evidenced by a 0.00% maximum drawdown.
CEO Commentary
The CEO emphasized progress in clinical trials for ozekibart (INBRX-109) and INBRX-106, with data expected in Q4 2025. He also highlighted disciplined financial management, including reduced R&D and G&A expenses post-spin-off, supporting operations into late 2025.
Guidance
No formal financial guidance was provided, but the company indicated that current cash reserves should sustain operations through its key data readouts.
Additional News
Recent news highlights include China and India potentially restoring direct flights as early as next month, U.S. officials expressing optimism about ending the conflict with Russia, and global economic indicators showing a slow but steady market recovery. Additionally, new developments in AI and robotics, along with geopolitical tensions, remain focal points in the broader news landscape.
Revenue
Driven entirely by a $1.30 million license fee, total revenue for in Q2 2025 surged 1200.0% year-over-year to $1.30 million from $100,000 in Q2 2024.
Earnings/Net Income
The company swung to a net loss of $28.65 million in Q2 2025, a 101.5% deterioration compared to net income of $1.86 billion in Q2 2024. Per-share earnings fell to a loss of $1.85, down from a profit of $127.10. Despite the sharp decline, the CEO noted that this marked a new Q2 net income record for the company.
Price Action
Inhibrx's stock gained 6.94% during the latest trading day, 12.35% for the week, and 2.66% month-to-date as of August 13, 2025.
Post-Earnings Price Action Review
A strategy of buying Inhibrx shares following its Q2 earnings release and holding for 30 days yielded a 28.67% return, outperforming the benchmark by 10.26%. The strategy’s Sharpe ratio of 0.41 indicated reasonable risk-adjusted returns, although it experienced no downside risk, as evidenced by a 0.00% maximum drawdown.
CEO Commentary
The CEO emphasized progress in clinical trials for ozekibart (INBRX-109) and INBRX-106, with data expected in Q4 2025. He also highlighted disciplined financial management, including reduced R&D and G&A expenses post-spin-off, supporting operations into late 2025.
Guidance
No formal financial guidance was provided, but the company indicated that current cash reserves should sustain operations through its key data readouts.
Additional News
Recent news highlights include China and India potentially restoring direct flights as early as next month, U.S. officials expressing optimism about ending the conflict with Russia, and global economic indicators showing a slow but steady market recovery. Additionally, new developments in AI and robotics, along with geopolitical tensions, remain focal points in the broader news landscape.
Ainvest Earnings Report Digest
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
Electrovaya 2025 Q4 Earnings Record Net Income Surges 1896.5% from Loss
Dec.20 2025
Winnebago Industries 2026 Q1 Earnings Record Revenue and 205.8% Net Income Turnaround
Dec.19 2025
Paychex 2026 Q2 Earnings Beats Revenue Estimates, EPS Falls Short
Dec.19 2025
Lamb Weston Holdings 2026 Q2 Earnings 272% Net Income Surge and 1.1% Revenue Growth
Dec.19 2025
ConAgra Brands 2026 Q2 Earnings Sharp Net Loss Amid Revenue Decline and EPS Drop
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet